Calcium antagonists and hypertension: Evolving perspectives - 1996

Cardiovascular Reviews and Reports

Volumn 17, Issue 2, 1996, Pages 30-42

  Epstein, Murray ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIURETIC AGENT; FELODIPINE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INSULIN; ISRADIPINE; MAGNESIUM; MINOXIDIL; NATRIURETIC FACTOR; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; POTASSIUM; RENIN; SODIUM; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL;

ADRENERGIC SYSTEM; BLOOD PRESSURE; CONSTIPATION; DRUG CONTRAINDICATION; DRUG RESPONSE; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; GENE; GLUCOSE INTOLERANCE; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; METABOLIC DISORDER; NONHUMAN; PLASMA RENIN ACTIVITY; REVIEW;

EID: 0030043940     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Triggle DJ. Biochemical and pharmacologic differences among calcium channel antagonists: Clinical implications. In: Epstein M (ed). Calcium Anlagonists in Clinical Medicine. Philadelphia. Hanley & Belfus; 1992:1-27.
2. Ram JL, Standley PR, Sowers JR. Calcium function in vascular smooth muscle and its relationship to hypertension. In: Epstein M (ed). Calcium Antagonists in Clinical Medicine. Philadelphia: Hanley & Belfus; 1992:29-48.
3. Epstein M. Calcium antagonists in the management of hypertension. In: Epstein M (ed). Calcium Antagonists in Clinical Medicine. Philadelphia: Hanley & Belfus; 1992:213-230.
4. Loutzenhiser R, Epstein M. Calcium antagonists and the kidney. Hosp Pract. 1987;22:63-76.
5. Epstein M. Calcium antagonists and renal protection: Current status and future perspectives. Arch Intern Med. 1992;152:1573-1584.
6. Epstein M, De Micheli AG. Natriuretic effects of calcium antagonists. In: Epstein M (ed). Calcium Antagonists in Clinical Medicine. Philadelphia: Hanley £Belfus; 1992:349-366.
7. Sowers JR The impact of diuretics on potassium and glucose. J Cardiavoic Pharmacol. 1984;6:5477-5482.
8. Weinberger MH. Anuhypertensive therapy and lipids. Arch Intern Med. 1985;145:1102-1105.
9. Berglund G, Anderson O, Widgren B. Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide. Acta Med Scand. 1986;220:419-424.
10. Samuel P, Kirkendall W, Shaefer EJ, et al Effects of isradipine, a new calcium antagonist, versus hydrochlorothiazide on serum lipids and apolipoproteins in patients with systemic hypertension. Am J Cardiol. 1988;62:1068-1071.
11. Lardinois CK, Neumann SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 1988;148:1280-1288.
12. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
13. Flack JM, Sowers JR. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med. 1991;91(1A):11-21.
14. Kaplan NM. Effects of antihypertensive therapy on insulin resistance. Hypertension. 1992;19:116-118.
15. Holland OB, Pool PE. Metabolic changes with antihypertensive therapy of the salt-sensitive patient. Am J Cordiol. 1988;61:53-59.
16. The Fifth Report of the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
17. Materson BJ, Epstein M. Thiazide diuretics, chlorthalidone, and metolazone. In: Messerli FH (ed), Cardiovascular Drug Therapy. Philadelphia: WB Saunders; 1990:337-347.
18. Ramsey LE, Yeo WW, Jackson PR, Influence of diuretics, calcium antagonists, and alpha-blockers on insulin sensitivity and glucose tolerance in hypertensive patients. J Cardiovasc Pharmacol. 1992;20(suppl 2):49-54.
19. Sowers JR. Is hypertension an insulin-resistant state? Metabolic changes associated with hypertension and antihypertensive therapy. Am Heart J 1991;122:932-935.
20. Sheu WH, Swislocki ALM, Hoffman B, et al. Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension. Am J Hypertens. 1991;4:199-205.
21. Shamoon H, Baylor P, Kambosos D, et al. Influence of oral verapamil on glucoregulatory hormones in man. J Clin Endocnnol Metab. 1985:60:536-541.
22. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203-209.
23. Trost BN, Weidman P. Effects of calcium antagonists on glucose homeostasis and serum lipids in nondiabetic and diabetic subjects - a review. J Hypertens. 1987:5(suppl 4):81-104.
24. Ferrier C, Ferrari P, Weidmann P, et al. Antihypertensive therapy with calcium-antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care. 1991;14:911-914.
25. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int. 1992;41:912-919.
26. Epstein M, Loutzenhiser R. Potential applicability of calcium antagonists as renal protective agents. In: Epstein M, Loutzenhiser R (eds). Calcium Antagonists and the Kidney. Philadelphia. Hanley & Belfus; 1990:275-298.
27. Loutzenhiser R, Epstein M, Horton C, et al. Reversal by the calcium antagonist nisoldipine, of norepinephrine-induced reduction of GFR: Evidence for preferential antagonism of pre-glomerular vasoconstriction. J Pharm Exp Ther. 1985;232:382-387.
28. Reams GP, Lau A, Bauer JH. Short-term and long-term renal response to nifedipine monotherapy. Am J Hypertens. 1989;2:188-190.
29. Epstein M. Renal effects of calcium antagonists with a focus on felodipine. Cardiavasc Drug Rev. 1994;12:344-356.
30. ter Wee P, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression on nondiabetic chronic renal disease. Arch Int Med. 1994;154:1185-1202.
31. Epstein M, De Micheli AG, Forster H. Natriuretic effects of calcium antagonists in humans: A review of experimental evidence and clinical data. Cardiovasc Drug Rev. 1991;9:399-413.
32. Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med. 1992;327:998-1008.
33. Eselin J, Carter B. Hypertension and left ventricular hypertrophy: Is drug therapy beneficial? Pharmacotherapy. 1994;14:60-88.
34. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: A meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
35. Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
36. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of incident myocardial infarction associated with antihypertensive drug therapies. Circulation. 1995;91:925.
37. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therzpies. JAMA. 1995;274:620-625.
38. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: A hypothesis formulated but not yet tesied. JAMA. 1995,274:654-655.
39. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med. 1995;155:2150-2156.
40. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis, and Management. 2nd Ed. New York: Raven Press; 1995:2815-2825.
41. Kleinbtoesem CH, van Brummelen P, Danhof M, et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther. 1987;41:26-30.
42. Frohlich ED, McLoughlin MJ, Losem CJ, et al. Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension. Am J Cardiol. 1991;68:1346-1350.
43. Phillips RA, Ardeljan M, Shimabukuro S, et al. Effects of nifedipine-GITS on left ventricular mass and left ventricular filling. J Cardiovasc Pharmacol. 1992;19(suppl 2):28-34.